Evidence map›Paper›PMID 34391593›Full record

ArticleVaccine2021

Enhancing influenza vaccine immunogenicity and efficacy through infection mimicry using silk microneedles.

Jordan A Stinson, Archana V Boopathy, Brian M Cieslewicz, Yichen Zhang, Nickolas W Hartman, David P Miller, Matthew Dirckx, Brett L Hurst, E Bart Tarbet, Jonathan A Kluge and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Exploiting Unique Features of Microneedles to Modulate Immunity.Advanced materials (Deerfield Beach, Fla.) · 2023
    Review
  11. Review
  12. Article
  13. Review
  14. Recent Updates in Vaccine Delivery through Microneedles.Advanced pharmaceutical bulletin · 2023
    Article
  15. Article
  16. Review
  17. Microneedle-Mediated Transdermal Delivery of Drug-Carrying Nanoparticles.Frontiers in bioengineering and biotechnology · 2022
    Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Jordan A StinsonVaxess Technologies, Inc., 790 Memorial Drive, Suite 200, Cambridge, MA 02139, USA.
Archana V BoopathyVaxess Technologies, Inc., 790 Memorial Drive, Suite 200, Cambridge, MA 02139, USA.
Brian M CieslewiczVaxess Technologies, Inc., 790 Memorial Drive, Suite 200, Cambridge, MA 02139, USA.
Yichen ZhangVaxess Technologies, Inc., 790 Memorial Drive, Suite 200, Cambridge, MA 02139, USA.
Nickolas W HartmanVaxess Technologies, Inc., 790 Memorial Drive, Suite 200, Cambridge, MA 02139, USA.
David P MillerVaxess Technologies, Inc., 790 Memorial Drive, Suite 200, Cambridge, MA 02139, USA.
Matthew DirckxVaxess Technologies, Inc., 790 Memorial Drive, Suite 200, Cambridge, MA 02139, USA.
Brett L HurstInstitute for Antiviral Research, Department of Animal, Dairy, and Veterinary Sciences, Utah State University, 5600 Old Main Hill, Logan, UT 84322, USA.
E Bart TarbetInstitute for Antiviral Research, Department of Animal, Dairy, and Veterinary Sciences, Utah State University, 5600 Old Main Hill, Logan, UT 84322, USA.
Jonathan A KlugeVaxess Technologies, Inc., 790 Memorial Drive, Suite 200, Cambridge, MA 02139, USA.
Kathryn M KosudaVaxess Technologies, Inc., 790 Memorial Drive, Suite 200, Cambridge, MA 02139, USA. Electronic address: kathryn@vaxess.com.
Vaxess Technologies (United States) · USUtah State University · US

Funding

Improved Influenza Vaccine Efficacy Through Infection MimicryR44AI142948 · NIAID · VAXESS TECHNOLOGIES, INC. · PI KOSUDA, KATHRYN · 2019 to 2021
$2.3M
NIAID NIH HHS HHSN272201700041INIAID NIH HHS R44 AI142948
6 · The paper itself

Abstract

Traditional bolus vaccine administration leads to rapid clearance of vaccine from lymphoid tissue. However, there is increasing evidence suggesting that the kinetics of antigen delivery can impact immune responses to vaccines, particularly when tailored to mimic natural infections. Here, we present the specific enhancements sustained release immunization confers to seasonal influenza vaccine, including the magnitude, durability, and breadth of humoral responses. To achieve sustained vaccine delivery kinetics, we have developed a microneedle array patch (MIMIX), with silk fibroin-formulated vaccine tips designed to embed in the dermis after a short application to the skin and release antigen over 1-2 weeks, mimicking the time course of a natural influenza infection. In a preclinical murine model, a single influenza vaccine administration via MIMIX led to faster seroconversion, response-equivalence to prime-boost bolus immunization, higher HAI titers against drifted influenza strains, and improved protective efficacy upon lethal influenza challenge when compared with intramuscular injection. These results highlight infection mimicry, achieved through sustained release silk microneedles, as a powerful approach to improve existing seasonal influenza vaccines, while also suggesting the broader potential of this platform technology to enable more efficacious next-generation vaccines and vaccine combinations.

Indexed as

Influenza, HumanInfluenza VaccinesAnimalsHumansImmunogenicity, VaccineMiceNeedlesSilkInfluenza VaccinesSilkInfection mimicryInfluenza vaccineMicroneedleSilk fibroinSustained release

Identifiers

PMID34391593
PMCPMC8405573
OpenAlexW3190023081

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.